Mechanisms of Fibronectin-Binding Protein A (fnbpa 110–263 ) Vaccine Efficacy in Staphylococcus Aureus Sepsis Versus Skin Infection

Rui Zhang,Sun Li,Xiao-Kai Zhang,Yu Wang,Yang,Hao Zeng,Da-Peng Yan,Quan-Ming Zou,Qian-Fei Zuo
DOI: https://doi.org/10.1016/j.clim.2018.05.007
IF: 10.19
2018-01-01
Clinical Immunology
Abstract:Increasing rates of life-threatening infections and decreasing susceptibility to antibiotics urge an effective vaccine targeting Staphylococcus aureus. Here we investigate the role of cellular immunity in FnBPA110-263 mediated protection in Staphylococcus aureus infection. This study revealed FnBPA110-263 broadly protected mice from seven FnBPA isotypes strains in the sepsis model. FnBPA110-263 immunized B-cell deficient mice were protected against lethal challenge, while T-cell deficient mice were not. Reconstituting mice with FnBPA110-263 specific CD4+ T-cells conferred antigen specific protection. In vitro assays indicated that isolated FnBPA110-263 specific splenocytes from immunized mice produced abundant IL-17A. IL-17A deficient mice were not protected from a lethal challenge by FnBPA110-263 vaccination. Moreover, neutralizing IL-17A, but not IFN-γ,reverses FnBPA110-263-induced protective efficacy in sepsis and skin infection model. These findings suggest that IL-17A producing Th17 cells play an essential role in FnBPA110-263 vaccine-mediated defense against S. aureus sepsis and skin infection in mice.
What problem does this paper attempt to address?